Advances in Chronic Kidney Disease
Volume 17, Issue 6 , Pages 493-506, November 2010

Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application

Mosaiques Diagnostics and Therapeutics, Hannover, Germany; BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom; INSERM Institut National de la Santé et de la Recherche Médicale (French Institute of Health and Medical Research), U858/I2MR, Department of Renal and Cardiac Remodeling, Team 5, Toulouse, France; and Université Toulouse III Paul Sabatier, Institut de Médecine Moléculaire de Rangueil, Toulouse, France

Use of capillary electrophoresis coupled to mass spectrometry (CE-MS) technology in proteome analysis has increased, with a focus on the identification of biomarker peptides in clinical proteomics. Among the reported applications, the main focus is on the urinary biomarkers for kidney disease. In this review, we discuss the principal, theoretical, and practical obstacles that are encountered when using CE-MS for the analysis of body fluids for biomarker discovery. We present several examples of a successful application of CE-MS for biomarker discovery in kidney disease, implications for disease diagnosis, prognosis, and therapy evaluation, and will also discuss current challenges and possible future improvements.

Key Words: Capillary electrophoresis, Mass spectrometry, Biomarker, Urine, Peptides, CKD

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Harald Mischak and Joost P. Schanstra are members of the EuroKUP consortium (www.eurokup.org).

 Harald Mischak is the founder and co-owner of Mosaiques Diagnostics, who developed the CE-MS technology for clinical application.

PII: S1548-5595(10)00143-6

doi:10.1053/j.ackd.2010.09.004

Advances in Chronic Kidney Disease
Volume 17, Issue 6 , Pages 493-506, November 2010

Article Tools

* Image Usage & Resolution